NLRP3 and cardiac hypertrophy: As a result, linagliptin improved cardiac contractility, suppressed mRNAs expression of NLRP3, ASC, IL-1β, collagen I, and collagen III in the border zone of myocardial infarction, and prevented cardiac hypertrophy both in wild-type (WT) and db/db mice[36].